Document is current
Any future updates will be listed below
-
Authors
Vosoughi, Aram https://orcid.org/0000-0001-8833-5136
Zhang, Tuo https://orcid.org/0000-0001-5396-918X
Shohdy, Kyrillus S.
Vlachostergios, Panagiotis J.
Wilkes, David C. https://orcid.org/0000-0002-2422-1145
Bhinder, Bhavneet
Tagawa, Scott T. https://orcid.org/0000-0003-2777-8587
Nanus, David M.
Molina, Ana M.
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
Sternberg, Cora N.
Motanagh, Samaneh
Robinson, Brian D.
Xiang, Jenny
Fan, Xiao
Chung, Wendy K.
Rubin, Mark A. https://orcid.org/0000-0002-8321-9950
Elemento, Olivier
Sboner, Andrea
Mosquera, Juan Miguel
Faltas, Bishoy M. https://orcid.org/0000-0002-6432-1693
- License Information
-
More Information
Article History
Received: 14 November 2019
Accepted: 10 November 2020
First Online: 3 December 2020
Competing interests
: S.T.T.: Consulting or Advisory Role: Medivation, Astellas Pharma, Dendreon, Janssen, Bayer, Genentech, Sanofi, Endocyte, Immunomedics. Speakers’ Bureau: Amgen. Research Funding: Eli Lilly (Inst), Sanofi (Inst), Janssen (Inst), Astellas Pharma (Inst), Progenics (Inst), Millennium (Inst), Amgen (Inst), Bristol-Myers Squibb (Inst), Dendreon (Inst), Rexahn Pharmaceuticals (Inst), Bayer (Inst), Genentech (Inst), Newlink Genetics (Inst), Inovio Pharmaceuticals (Inst), AstraZeneca (Inst), Immunomedics (Inst), Novartis (Inst), AVEO (Inst), Rexahn Pharmaceuticals (Inst), Boehringer Ingelheim (Inst), Merck (Inst), Stem CentRx (Inst). Travel, Accommodations, Expenses: Sanofi. D.M.N.: Consulting or Advisory Role: Genentech. A.M.M.: Honoraria: ASCO. Consulting or Advisory Role: Eisai, Exelixis, Novartis. Himisha Beltran: Consulting or Advisory Role: Bayer, Janssen Oncology, Genzyme. Research Funding: Astellas Pharma (Inst), Eli Lilly (Inst), Janssen (Inst), Millennium (Inst), Stemcentryx Abbvie. C.N.S.: Consulting or Advisory Role: Pfizer, Merck, AstraZeneca, Astellas Pharma, Sanofi-Genzyme, Roche/Genentech, Incyte, Medscape, Clovis Oncology, UroToday, MSD. B.D.R.: Stock and Other Ownership Interests: Metastat. Consulting or Advisory Role: Progenics Pharmaceuticals Patents, Royalties, Other Intellectual Property: Methods for diagnosing and treating prostate cancer. Mark Rubin: Research Funding: Eli Lilly, Janssen. Olivier Elemento: Stock and Other Ownership Interests: Volastra, Owkin, One Three Biotech. B.M.F.: Consulting or Advisory Role: Immunomedics, Merck & Co, Research support: Eli Lilly. A.V., T.Z., K.S.S., P.J.V., D.C.W., B.B., S.M., J.X., X.F., W.K.C., A.S., and J.M.M. declare no competing interests.
